Drug Search Results
More Filters [+]

Lersivirine

Alternative Names: lersivirine, uk-453061, uk453061, uk 453061, uk-453,061, uk453,061, uk 453,061, UK-453, 061
Latest Update: 2018-12-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: NNRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lersivirine

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: HIV Infections

Phase 1: HIV Infections|Healthy Volunteers|Cross Infection|Tuberculosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

HER2E-PAM, PAMILIA Study

N/A

Not yet recruiting

Enterocolitis|Intestinal Diseases

2023-03-01

2008-006049-26

P2

Terminated

HIV Infections

2013-07-15

2010-020860-39

P2

Terminated

HIV Infections

2013-04-30

A5271037

P2

Terminated

HIV Infections

2013-04-01

Recent News Events

Date

Type

Title